Jacobio Pharmaceuticals Group Co., Ltd.

1167.HK · HKSE

Company research

Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) is a clinical-stage biopharmaceutical investment holding company headquartered in Beijing, China, founded in 2015 and listed on the Hong Kong Stock Exchange in December 2020. The company specializes in the in-house discovery and development of innovative oncology therapies, leveraging its proprietary Induced Allosteric Drug Discovery Platform (IADDP) to target proteins that are difficult to drug with conventional approaches, with core projects centered on the KRAS pathway. Its robust pipeline includes key candidates such as sitneprotafib (JAB-3312), an allosteric SHP2 inhibitor in Phase III trials for non-small cell lung cancer, glecirasib (JAB-21822), a KRAS G12C inhibitor in Phase II trials, and JAB-23E73, an oral pan-KRAS inhibitor being developed in collaboration with AstraZeneca. With R&D centers in Beijing, Shanghai, and Boston, and clinical trials spanning over 180 sites across China, the US, and Europe, Jacobio is positioned as a leading innovator in global oncology drug development.

Research reports

CMB International Global Markets (CMBIGM) · March 12, 2026Jacobio (1167 HK) - Early pan-KRAS clinical data unveils potential first-in-class blockbuster

CMB International Global Markets provides a company update arguing that Jacobio’s pan-KRAS inhibitor JAB-23E73 has a highly differentiated safety profile and promising early efficacy versus competitors, supporting potential first-in-class blockbuster status and a risk-adjusted global peak sales estimate of US$2.1 billion. The report highlights Jacobio’s robust cash position, including an anticipated US$1 billion upfront payment from AstraZeneca, maintains a BUY rating with a HK$10.34 target price implying 45.8% upside, and discusses ongoing clinical development milestones across KRAS and ADC programs while noting general investment and clinical trial risks in its standard disclosures.